# EDGAR Filing Document

**Accession Number:** 0001655759
**File Stem:** 0001628280-26-009296
**Filing Date:** 2026-2
**Character Count:** 18834
**Document Hash:** b70dca1bd844d6d3f5923cf708aa8d96
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-009296.hdr.sgml**: 20260218

**ACCESSION NUMBER**: 0001628280-26-009296

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 4

**CONFORMED PERIOD OF REPORT**: 20260212

**FILED AS OF DATE**: 20260218

**DATE AS OF CHANGE**: 20260218

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Teel Randy
- **CENTRAL INDEX KEY:** 0002015998

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38672
- **FILM NUMBER:** 26650675

**MAIL ADDRESS:**
- **STREET 1:** C/O ARVINAS, INC.
- **STREET 2:** 5 SCIENCE PARK, 395 WINCHESTER AVE.
- **CITY:** NEW HAVEN
- **STATE:** CT
- **ZIP:** 06511
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ARVINAS, INC.
- **CENTRAL INDEX KEY:** 0001655759
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 472566120
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 395 WINCHESTER AVE
- **STREET 2:** 5 SCIENCE PARK
- **CITY:** NEW HAVEN
- **STATE:** CT
- **ZIP:** 06511
- **BUSINESS PHONE:** 203-535-1456

**MAIL ADDRESS:**
- **STREET 1:** 395 WINCHESTER AVE
- **STREET 2:** 5 SCIENCE PARK
- **CITY:** NEW HAVEN
- **STATE:** CT
- **ZIP:** 06511

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ARVINAS INC.
- **DATE OF NAME CHANGE:** 20181001

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ARVINAS HOLDING COMPANY, LLC
- **DATE OF NAME CHANGE:** 20151015

## Exhibit 24.1

![](arvn_-xsectionx16xxxform001.jpg)

POWER OF ATTORNEY The undersigned hereby makes, constitutes and appoints each of Andrew Saik, Jared Freedberg, Christina Bailey and Artur Sztyler, or each of them acting singly, and with full power of substitution, re- substitution and delegation, the undersigned's true and lawful attorney-in-fact (each of such persons and their substitutes and delegees being referred to herein as the "Attorney-in-Fact"), with full power to act for the undersigned and in the undersigned's name, place and stead, in the undersigned's capacity as an officer, director or stockholder of Arvinas, Inc. (the "Company"), to: 1. Take such actions as may be necessary or appropriate to enable the undersigned to submit and file forms, schedules and other documents with the U.S. Securities and Exchange Commission ("SEC") utilizing the SEC's Electronic Data Gathering and Retrieval ("EDGAR") system, which actions may include (a) enrolling the undersigned in EDGAR Next and (b) preparing, executing and submitting to the SEC a Form ID, amendments thereto, and such other documents and information as may be necessary or appropriate to obtain and/or modify codes and passwords enabling the undersigned to make filings and submissions utilizing the EDGAR system; 2. Prepare and execute any and all forms, schedules and other documents (including any amendments thereto) the undersigned is required to file with the SEC, or which the Attorney- in-Fact considers it advisable for the undersigned to file with the SEC, under Section 13 or Section 16 of the Securities Exchange Act of 1934 or any rule or regulation thereunder, or under Rule 144 under the Securities Act of 1933 ("Rule 144"), including Forms 3, 4 and 5, Schedules 13D and 13G, and Forms 144 (all such forms, schedules and other documents being referred to herein as "SEC Filings"); 3. Submit and file SEC Filings with the SEC utilizing the EDGAR system or any such third-party system with which the Company, the undersigned or the Attorney-in-Fact uses to make EDGAR filings with the SEC or cause them to be submitted and filed by a person appointed under Section 5 below; 4. File, submit or otherwise deliver SEC Filings to any securities exchange on which the Company's securities may be listed or traded; 5. Act as an account administrator for the undersigned's EDGAR account, including: (i) appoint, remove and replace account administrators, account users, technical administrators and delegated entities; (ii) maintain the security of the undersigned's EDGAR account, including modification of access codes; (iii) maintain, modify and certify the accuracy of information on the undersigned's EDGAR account dashboard; (iv) act as the EDGAR point of contact with respect to the undersigned's EDGAR account; and (v) any other actions contemplated by Rule 10 of Regulation S-T with respect to account administrators; or act as a delegated administrator for the undersigned's EDGAR account, including: (i) appoint, remove and replace delegated account administrators and users; (ii) maintain the security of the undersigned's EDGAR account; and (iii) any other actions contemplated by Rule 10 of Regulation S-T with respect to delegated entities; 6. Cause the Company to accept a delegation of authority from any of the undersigned's EDGAR account administrators and, pursuant to that delegation, authorize the Company's EDGAR account administrators to appoint, remove or replace users for the undersigned's EDGAR account; and 7. Obtain, as the undersigned's representative and on the undersigned's behalf, information regarding transactions in the Company's equity securities from any third party, including the Docusign Envelope ID: 5062A8A6-2EAB-4A7B-8A08-F3059E067EA6

------

![](arvn_-xsectionx16xxxform002.jpg)

Company and any brokers, dealers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such third party to release any such information to the Attorney-in-Fact. The undersigned acknowledges that: a) This Power of Attorney authorizes, but does not require, the Attorney-in-Fact to act in his or her discretion on information provided to such Attorney-in-Fact without independent verification of such information; b) Any documents prepared or executed by the Attorney-in-Fact on behalf of the undersigned pursuant to this Power of Attorney will be in such form and will contain such information as the Attorney-in-Fact, in his or her discretion, deems necessary or desirable; c) Neither the Company nor the Attorney-in-Fact assumes any liability for the undersigned's responsibility to comply with the requirements of Section 13 or Section 16 of the Exchange Act or Rule 144, any liability of the undersigned for any failure to comply with such requirements, or any liability of the undersigned for disgorgement of profits under Section 16(b) of the Exchange Act; and d) This Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under Section 13 or Section 16 of the Exchange Act, including, without limitation, the reporting requirements under Section 13 or Section 16 of the Exchange Act. The undersigned hereby grants to the Attorney-in-Fact full power and authority to do and perform each and every act and thing requisite, necessary or advisable to be done in connection with the foregoing, as fully, to all intents and purposes, as the undersigned might or could do in person, hereby ratifying and confirming all that the Attorney-in-Fact, or his or her substitute or substitutes, shall lawfully do or cause to be done by authority of this Power of Attorney. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 4 or 5 or Schedules 13D or 13G or Forms 144 with respect to the undersigned's holdings of and transactions in securities of the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Attorney-in-Fact. This Power of Attorney revokes all previous powers of attorney with respect to the subject matter of this Power of Attorney. IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney as of February 12, 2026. Signature Randy Teel, Ph.D. Print Name Docusign Envelope ID: 5062A8A6-2EAB-4A7B-8A08-F3059E067EA6

------

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Teel Randy<br><sub>(Last) (First) (Middle)</sub><br>C/O ARVINAS, INC.<br>5 SCIENCE PARK, 395 WINCHESTER AVE.<br><sub>(Street)</sub><br>NEW HAVEN, CT 06511<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>ARVINAS, INC. [ ARVN ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-02-12 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_President and CEO_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 12396<sup>(1)</sup> | D |  |
| Common Stock | 59600<sup>(2)</sup> | D |  |
| Common Stock | 46638<sup>(3)</sup> | D |  |
| Common Stock | 11072<sup>(4)</sup> | D |  |
| Common Stock | 18713<sup>(5)</sup> | D |  |
| Common Stock | 10466<sup>(6)</sup> | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Option (right to buy) | <sup>(7)</sup> | 2035-05-08 | Common Stock | 91000 | $6.61 | D |  |
| Stock Option (right to buy) | <sup>(8)</sup> | 2035-02-12 | Common Stock | 71212 | $17.67 | D |  |
| Stock Option (right to buy) | <sup>(9)</sup> | 2034-05-20 | Common Stock | 19675 | $34.65 | D |  |
| Stock Option (right to buy) | <sup>(10)</sup> | 2034-02-22 | Common Stock | 34161 | $47 | D |  |
| Stock Option (right to buy) | <sup>(11)</sup> | 2033-02-21 | Common Stock | 38350 | $34.37 | D |  |
| Stock Option (right to buy) | <sup>(12)</sup> | 2032-02-22 | Common Stock | 52400 | $64.19 | D |  |
| Stock Option (right to buy) | <sup>(13)</sup> | 2031-02-25 | Common Stock | 37000 | $78.30 | D |  |
| Stock Option (right to buy) | <sup>(14)</sup> | 2030-02-26 | Common Stock | 40000 | $47.38 | D |  |
| Stock Option (right to buy) | <sup>(15)</sup> | 2029-02-28 | Common Stock | 46945 | $19.36 | D |  |
| Stock Option (right to buy) | <sup>(16)</sup> | 2028-09-25 | Common Stock | 104605 | $16 | D |  |

---

### Footnotes:

(1) Includes 1,509 shares of common stock of the Issuer previously purchased by the reporting person under the issuer's 2018 Employee Stock Purchase Plan.

(2) The restricted stock units (each, an "RSU") were granted by the Issuer on May 9, 2025, pursuant to its 2018 Stock Incentive Plan (the "Plan") and each RSU represents a contingent right to receive one share of the issuer's common stock upon settlement for no consideration. The RSUs vest over two years: 1/2 of the shares underlying the award will vest on May 9, 2026, with the remainder of the shares vesting on May 9, 2027, subject to the reporting person's continued service with the Issuer on each vesting date.

(3) The RSUs were granted by the Issuer on February 13, 2025, pursuant to its Plan and each RSU represents a contingent right to receive one share of the issuer's common stock upon settlement for no consideration. The RSUs vest over four years: 25% of the RSUs will vest on each of February 13, 2026, February 13, 2027, February 13, 2028 and February 13, 2029, subject to the reporting person's continued service with the Issuer on each vesting date.

(4) The RSUs were granted by the Issuer on May 21, 2024, in connection with the reporting person being named as Chief Business Officer of the Issuer, pursuant to its Plan and each RSU represents a contingent right to receive one share of the issuer's common stock upon settlement for no consideration. The RSUs vest over two years: 1/2 of the shares underlying the award vested on May 21, 2025, with the remainder of the shares vesting on May 21, 2026, subject to the reporting person's continued service with the Issuer on each vesting date. The RSU amount reflects that 2,228 shares were sold to pay for taxes following the May 21, 2025 vesting.

(5) The RSUs were granted by the Issuer on February 23, 2024, pursuant to its Plan and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs vest over two years: 1/2 of the shares underlying the award vested on February 23, 2025, with the remainder of the shares vesting in on February 23, 2026, subject to the reporting person's continued service with the Issuer on each vesting date. The RSU amount reflects that 4,380 shares were sold to pay for taxes following the February 23, 2025 vesting.

(6) The RSUs were granted by the Issuer on February 22, 2023, pursuant to the Plan and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration.  The RSUs vest over four years:  25% of the RSUs vested on each of February 22, 2024 and February 22, 2025, with the remaining RSUs vesting on each of February 22, 2026 and February 22, 2027, subject to the reporting person's continued service with the Issuer on each vesting date. The RSU amount reflects that 1,184 and 1,125 shares were sold to pay for taxes following the February 22, 2024 and February 22, 29025 vestings, respectively.

(7) The option was granted by the Issuer on May 9, 2025, pursuant to the Plan. The shares underlying the option will vest over two years: 1/2 of the shares underlying the award shall vest on May 9, 2026, with the remainder of the shares vesting on May 9, 2027, subject to the reporting person's continued service with the Issuer on each vesting date.

(8) The option was granted by the Issuer on February 13, 2025, pursuant to the Plan. The shares underlying the option vest over four years: 1/4 of the shares underlying the award will vest on February  13, 2026, with the remainder of the shares vesting in equal monthly installments following February 13, 2026 through February 13, 2029, subject to the reporting person's continued service with the  Issuer on each vesting date.

(9) The option was granted by the Issuer on May 21, 2024, in connection with the reporting person being named as Chief Business Officer of the Issuer, pursuant to the Plan. The shares underlying the option vest over two years: 1/2 of the shares underlying the award vested on May 21, 2025, with the remainder of the shares vesting on May 21, 2026, subject to the reporting person's continued service with the  Issuer on each vesting date.

(10) The option was granted by the Issuer on February 23, 2024, pursuant to the Plan. The shares underlying the option vest over two years: 1/2 of the shares underlying the award vested on February 23, 2025, with the remainder of the shares vesting on February 23, 2026, subject to the reporting person's continued service with the  Issuer on each vesting date.

(11) The option was granted by the Issuer on February 22, 2023, pursuant to the Plan. The shares underlying the option vest over four years: 1/4 of the shares underlying the award vested on February 22, 2024, with the remainder of the shares vesting in equal monthly installments following February 22, 2024 through February 23, 2027, subject to the reporting person's continued service with the  Issuer on each vesting date.

(12) The option was granted by the Issuer on February 23, 2022, pursuant to the Plan. The shares underlying the option vest over four years: 1/4 of the shares underlying the award vested on February 23, 2023, with the remainder of the shares vesting in equal monthly installments following February 23, 2023 through February 23, 2026, subject to the reporting person's continued service with the  Issuer on each vesting date.

(13) The option was granted by the Issuer on February 26, 2021, pursuant to the Plan. The shares underlying the option vested over four years: 1/4 of the shares underlying the award vested on February 26, 2022, and the remainder of the shares vested in equal monthly installments following February 23, 2022 through February 23, 2025.

(14) The option was granted by the Issuer on February 27, 2020, pursuant to the Plan. The shares underlying the option vested over four years: 1/4 of the shares underlying the award vested on February 27, 2021, and the remainder of the shares vested in equal monthly installments following February 27, 2021 through February 27, 2024.

(15) The option was granted by the Issuer on March 1, 2019, pursuant to the Plan. The shares underlying the option vested over four years: 1/4 of the shares underlying the award vested on March 1, 2020, and the remainder of the shares vested in equal monthly installments following March 1, 2020 through March 1, 2023.

(16) The option was granted by the Issuer on September 26, 2018, pursuant to the Plan. The shares underlying the option vested over four years: 1/4 of the shares underlying the award vested on May 14, 2019, and the remainder of the shares vested in equal monthly installments following May 14, 2019 through May 14, 2022.

**Signature:** /s/ Jared Freedberg, as attorney-in-fact for Randy Teel  
**Date:** 2026-02-18

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**